Regeneron Pharmaceuticals Up Over 6%, On Pace for Highest Close Since November 2015 -- Data Talk

Regeneron Pharmaceuticals, Inc. (REGN) is currently at $574.69, up $32.87 or 6.07%

-- Would be highest close since Nov. 20, 2015, when it closed at $579.57

-- On pace for largest percent increase since March 17, 2020, when it rose 11.54%

-- Earlier Tuesday, Regeneron Pharmaceuticals reported first-quarter earnings of $624.6 million, or $5.43 a share, in the first quarter, compared with $461.1 million, or $3.99 a year ago. Adjusted earnings were $6.60 a share. Analysts had forecasted adjusted earnings of $5.25 a share. Sales were $1.83 billion in the quarter, up from $1.37 billion a year ago. Analysts had expected $1.76 billion

-- The company said human trials of a new Covid-19 drug are slated to begin in summer. The drugmaker said its novel antibody cocktail, REGN-COV2, could be used to prevent and treat Covid-19 and will enter human trials in June, said Leonard Schleifer, chief executive at Regeneron

-- Regeneron Pharmaceuticals and Sanofi SA on Tuesday said Libtayo showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma in an open-label phase 2 study

-- Up 53.05% year-to-date

-- Down 2.99% from its all-time closing high of $592.40 on Aug. 5, 2015

-- Up 78.25% from 52 weeks ago (May 7, 2019), when it closed at $322.40

-- Would be a new 52 week closing high

-- Up 110.16% from its 52 week closing low of $273.46 on Sept. 27, 2019

-- Traded as high as $581.00; highest intraday level since Nov. 23, 2015, when it hit $584.59

-- Up 7.23% at today's intraday high; largest intraday percent increase since March 23, 2020, when it rose as much as 8.79%

-- Ninth best performer in the S&P 500 today

-- Third best performer in the Nasdaq 100 today

All data as of 11:47:42 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

May 05, 2020 12:14 ET (16:14 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.